Search for European Projects

38 European Projects Found

Searched on 125080 European Projects

 FINISHED 
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Read Project

 43

 FINISHED 
Abstract 9Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standard ...
Read Project

 24

 FINISHED 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Read Project

 29

 FINISHED 

Hepatic and Cardiac Toxicity Systems modelling (HECATOS)

Start date: Oct 1, 2013, End date: Sep 30, 2018,

HeCaToS aims at developing integrative in silico tools for predicting human liver and heart toxicity. The objective is to develop an integrated modeling framework, by combining advances in computational chemistry and systems toxicology, for modelling toxic perturbations in liver and heart across multiple scales. This framework will include vertical integrations of representations from drug(metabol ...
Read Project

 14

 FINISHED 

European Medical Information Framework (EMIF)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Read Project

 64

 FINISHED 
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Read Project

 26

 FINISHED 

Kinetics for Drug Discovery (K4DD) (K4DD)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Read Project

 21

 FINISHED 
Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Read Project

 17

 FINISHED 
IN-SENS is an interdisciplinary, cutting-edge European industry-academia collaborative effort for a novel training of scientists in molecular psychiatry with the prospect of discovering the biology of schizophrenia and actively promote drug discovery. Mental illnesses are a major burden to patients, relatives, and public health worldwide. IN-SENS therefore aims to profoundly change the academic-in ...
Read Project

 16

 FINISHED 

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE (DRIVE-AB)

Start date: Oct 1, 2014, End date: Sep 30, 2017,

Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements ...
Read Project

 27

 FINISHED 
StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Read Project

 38

 FINISHED 
Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improveme ...
Read Project

 20

 FINISHED 
Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Read Project

 29

 FINISHED 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Read Project

 33

 FINISHED 
We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Read Project

 22

 FINISHED 

Incorporating real-life clinical data into drug development (GETREAL)

Start date: Oct 1, 2013, End date: Dec 31, 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Read Project

 32

 FINISHED 
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Read Project

 30

 FINISHED 
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project

 34

 FINISHED 

European Medicines Research Training Network (EMTRAIN)

Start date: Oct 1, 2009, End date: Sep 30, 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Read Project

 32

 FINISHED 

Drug Disease Model Resources (DDMORE)

Start date: Mar 1, 2011, End date: Aug 31, 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project

 28

 FINISHED 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Start date: Sep 1, 2009, End date: Jun 30, 2016,

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Read Project

 24

 FINISHED 
Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel th ...
Read Project

 23

 FINISHED 

Electronic Health Record systems for Clinical Research (EHR4CR)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Read Project

 37

 FINISHED 
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Read Project

 38

 FINISHED 
Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as we ...
Read Project

 27

 FINISHED 
In the understanding of the initiation and development of several diseases revolutionary changes are currently taking place. Cancer and brain diseases are examples of medical fields where new technologies are finding their way into research and applications, radically altering the way the diseases are being diagnosed and treated. Especially methods that yield information on molecular and cellular ...
Read Project

 10

 FINISHED 
An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Read Project

 23

 FINISHED 
RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding.HypothesisThe use of biomarker profiles comprised of various types of hi ...
Read Project

 42

 FINISHED 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Start date: Jun 15, 2009, End date: Jun 14, 2015,

The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Read Project

 26

 FINISHED 
Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Read Project

 36

 FINISHED 
Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are few novel treatments. We think this is because of three major “bottle-necks”: a lack of etiologically-driven or pathophysiologically-accurate animal models; a lack of tests that provide indication of efficacy in healthy volunteers; and the reliance of clinical ...
Read Project

 20

 FINISHED 
Individualisation of cancer therapy based on standardized biomarker assays is one of the most demanding challenges in cancer medicine. In the RESPONSIFY consortium, we will integrate information on response prediction from different breast cancer types and methodologies into biomarker tests for targeted therapies in the clinical routine setting. Those tests will be developed for commercialisation ...
Read Project

 14

 FINISHED 
Inhibition of angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a well established therapeutic strategy against cancer. Inhibitors of angiogenesis have been developed to block tumour growth and metastasis, and a number of these inhibitors are now clinically approved. However, contrary to initial expectations, angiogenesis inhibitors can cause a range of toxicities ...
Read Project

 11

 FINISHED 
"To maintain homeostasis of the central nervous system (CNS) the blood-brain barrier (BBB) prevents the free transcellular passage of hydrophilic molecules from the blood into the CNS. Because of this, the BBB is now recognised as the major obstacle to the treatment of most neurological disorders, as it hinders the delivery of many potentially important therapeutic and diagnostic substances to the ...
Read Project

 8

 FINISHED 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Start date: May 1, 2009, End date: Apr 30, 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Read Project

 52

 FINISHED 
eHealth Innovation TN will develop consensus among stakeholders and recommendations to-wards making innovative integrated, and therefore interoperable eHealth services operational and deployed at large scale in Europe.The focus will be to analyse, achieve consensus on and deliver a detailed summary report on how to achieve in the medium-term more patient/person-centred health services for an agein ...
Read Project

 22

 FINISHED 

Embryonic Stem cell-based Novel Alternative Testing Strategies (ESNATS)

Start date: Apr 1, 2008, End date: Sep 30, 2013,

"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to ...
Read Project

 34

 FINISHED 

Computational Prediction of Drug Cardiac Toxicity (preDiCT)

Start date: Jun 1, 2008, End date: May 31, 2011,

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions o ...
Read Project

 9